Galectin Therapeutics Inc.

GALT · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$8,184-$7,521-$9,631-$11,967
Dep. & Amort.$0$2$10$10
Deferred Tax$0$0$0$0
Stock-Based Comp.$496$500$468$0
Change in WC$1,726-$1,028$1,092$326
Other Non-Cash$2,420$1,445$372-$1,160
Operating Cash Flow-$3,542-$6,602-$7,689-$12,791
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$0$11,000$0$0
Stock Issued$853$1,942$0$851
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$443$0$0$0
Financing Cash Flow$1,296$12,942$0$851
Forex Effect$0$0$0$0
Net Chg. in Cash-$2,246$6,340-$7,689-$11,940
Supplemental Information
Beg. Cash$13,771$7,431$15,120$27,060
End Cash$11,525$13,771$7,431$15,120
Free Cash Flow-$3,542-$6,602-$7,689-$12,791
Galectin Therapeutics Inc. (GALT) Financial Statements & Key Stats | AlphaPilot